Zimmer Biomet Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Zimmer Biomet Holdings, Inc. on June 13, 2016. The filing reports on a material definitive agreement entered into on June 13, 2016, regarding a secondary offering of common stock by certain selling stockholders, with the transaction completed on June 16, 2016.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a stock sale by existing shareholders.
- Shares Sold: 11,116,533 shares of common stock.
- Proceeds: The Company will not receive any proceeds from this sale; proceeds go to the Selling Stockholders.
- Selling Stockholders: Affiliates of Kohlberg Kravis Roberts & Co. L.P., The Goldman Sachs Group, Inc., or TPG Global, LLC.
- Underwriters: Goldman, Sachs & Co. and J.P. Morgan Securities LLC.
Material Changes
The primary material change is the reduction in ownership concentration by the Selling Stockholders, who collectively held more than 9.3% of the Company's outstanding shares prior to the transaction. This sale triggers a "Principal Stockholder Rights Termination Event" under the existing Stockholders Agreement.
Outlook, Risks, and Governance Changes
Governance Impact: The termination event results in the Selling Stockholders losing the right to designate members of the Board of Directors. Specifically, designated directors Michael W. Michelson and Jeffrey K. Rhodes are obligated to resign, though the Company has temporarily waived this obligation until the second business day following the first regularly scheduled board meeting in July 2016 to allow for discussion on future board composition.
Risks and Contingencies: The Company has agreed to indemnify the Underwriters against certain liabilities on customary terms. The filing notes that the Underwriters and their affiliates have provided and may continue to provide commercial banking and financial services to the Company for customary fees.
Investor Verification Checklist
- Verify the final pricing of the 11,116,533 shares sold by reviewing the press release dated June 14, 2016 (Exhibit 99.2).
- Confirm the resignation status of directors Michael W. Michelson and Jeffrey K. Rhodes following the July 2016 board meeting.
- Review the Underwriting Agreement (Exhibit 1.1) for specific indemnification terms and customary covenants.
- Check subsequent filings for the updated beneficial ownership percentages of the Selling Stockholders post-transaction.